Structure via PubChem · Public domain (PubChem)
洛莫司汀
Sign in to saveAlso known as CCNU, CeeNU®, N-(2-chloroethyl)-N'-cyclohexyl-N-nitrosourea, 1-(2-chloroethyl)-3-cyclohexylnitrosourea, CINU, cyclohexyl chloroethyl nitrosourea, chloroethylcyclohexylnitrosourea, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea
化合物
In the Vinony graph
Within Vinony's link graph, 洛莫司汀 is referenced by 294 other articles, and connects out to nitrosourea, tiazofurin and liver.
It sits within the topics Alkylating antineoplastic agents, Cancer treatments and Chloroethyl compounds.
Its subject is documented across 22 Wikipedia language editions.
Key facts
- Drug.N
- 3
- Drug.O
- 2
- Drug.H
- 16
- Drug.Cl
- 1
- Drug.Verifiedfields
- changed
- Drug.Watchedfields
- changed
- Drug.verifiedrevid
- 462093427
- Drug.IUPAC_name
- N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea
- Drug.image
- Lomustine.svg
- Drug.image_class
- skin-invert-image
- Drug.width
- 200
- Drug.image2
- Lomustine ball-and-stick model.png
- Drug.image_class2
- bg-transparent
- Drug.width2
- 175
- Drug.tradename
- Gleostine, CCNU, CeeNu, CuuNu
- Drug.MedlinePlus
- a682207
- Drug.pregnancy_US
- D
- Drug.legal_CA
- Rx-only
via Wikipedia infobox
Chemical data
- Formula
- C9H16ClN3O2
- Molecular weight
- 233.69 g/mol
- IUPAC name
- 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea
- SMILES
- C1CCC(CC1)NC(=O)N(CCCl)N=O
- InChIKey
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N
- XLogP
- 2.8
- Polar surface area
- 61.8 Ų
- H-bond donors
- 1
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 1976
- Admin. routes
- oral
- Indications
- neoplasm, glioblastoma multiforme, acute myeloid leukemia, anaplastic astrocytoma
via ChEMBL · EBI
Research
3,011 papers- Lomustine and Bevacizumab in Progressive Glioblastoma.The New England journal of medicine · 2017
- Lomustine, methotrexate and cytarabine chemotherapy as a rescue treatment for feline lymphoma.Journal of feline medicine and surgery · 2021
- Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial.The Lancet. Oncology · 2019
- How did lomustine become standard of care in recurrent glioblastoma?Cancer treatment reviews · 2020
- Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.The Lancet. Oncology · 2014
via PubMed
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 233.093
- Has use
- medication
Show 6 more facts
- chemical formula
- C₉H₁₆ClN₃O₂
- medical condition treated
- Hodgkin lymphoma
- legal status (medicine)
- boxed warning
- canonical SMILES
- C1CCC(CC1)NC(=O)N(CCCl)N=O
- World Health Organisation international non-proprietary name
- lomustine
- Commons category
- Lomustine
Sources (8)
via Wikidata · CC0
Gallery (2)
Connections
nitrosourea
Entity
tiazofurin
Entity
liver
Entity
deoxyribonucleic acid
Entity
International Standard Book Number
Entity
ribonucleic acid
Entity
digital object identifier
Entity
International Standard Serial Number
Entity
chemical formula
Entity
melting point
Entity
chemotherapy
Entity
molar mass
Entity
PubMed
Entity
brain tumor
Entity
DNA replication
Entity
hydrazine
Entity
cell cycle
Entity
DL-asparagine
Entity
CAS Registry Number
Entity
Hodgkin lymphoma
Entity